Compugen (CGEN) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Phase 1 study “A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies” tests Compugen’s COM902 cancer drug alone and in combinations. It aims to find safe dosing, assess early anti-tumor signals, and support later-stage trials that could expand the company’s immuno-oncology pipeline.
The main treatments are COM902 on its own and COM902 with COM701, both given by IV every 3 weeks. In some groups, these are also combined with Merck’s Keytruda (pembrolizumab) to see if a triplet mix can boost benefit in tough cancers like MSS colorectal and platinum-resistant ovarian cancer.
This is an interventional Phase 1 trial with no randomization and no placebo group, so all patients receive study drugs. It uses a stepwise dose-escalation design followed by expansion groups and is open label, meaning doctors and patients know which treatment they are getting, with a primary goal of treatment and safety.
The trial was first submitted on 2020-04-15, marking the start of its regulatory record and early enrollment phase. The last update was filed on 2026-05-11, indicating the sponsor has recently refreshed key details, which often signals that data review or planning for next steps in development is under way.
The study is now listed as completed, so investors in Compugen (CGEN) can expect an information overhang as they wait for topline safety and activity data. Positive signals could strengthen confidence in the TIGIT program, support partnering talks and lift sentiment, while weak data may pressure the stock and favor rivals in the checkpoint space.
This update also matters in a crowded immunotherapy market where big pharma is advancing their own TIGIT and combo strategies. Any sign that COM902 plus COM701 and Keytruda can help hard-to-treat solid tumors could differentiate Compugen’s approach and shift attention back to smaller-cap immune-oncology names.
The COM902 Phase 1 trial has completed but remains actively updated, and further details are available on the ClinicalTrials portal for investors tracking the program’s progress.
To learn more about CGEN’s potential, visit the Compugen drug pipeline page.